Get the full picture
Sign in to uncover key details.
Tactiva Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
701 Ellicott St Fl 4, Buffalo, New York,...Phone Number
(716) 536-2971Website
www.tactivatherapeutics.comRevenue
<$5 MillionIndustry
About Tactiva Therapeutics
Tactiva Therapeutics is an immuno-oncology company focused on developing innovative cancer immunotherapy through a dual T cell receptor approach. Their Next Generation adoptive cell therapy strategies aim to deliver effective and sustained immune responses against tumors by utilizing both CD8 and CD4 T cell receptors. The company has created a library of T cell receptors that enhance the anti-tumor function and provide a long-term source of cancer-fighting T cells through the reprogramming of hematopoietic stem cells. Tactiva Therapeutics targets solid tumors, offering a promising solution for durable remission in cancer patients.Explore more
Tactiva Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Tactiva Therapeutics
Compare insights from companies similar to Tactiva Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tactiva Therapeutics Tech Stack
A closer look at the technologies used by Tactiva Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tactiva Therapeutics
Sign Up For FreeTo access detailed company insights
Tactiva Therapeutics is an immuno-oncology company focused on developing innovative cancer immunotherapy through a dual T cell receptor approach. Their Next Generation adoptive cell therapy strategies aim to deliver effective and sustained immune responses against tumors by utilizing both CD8 and CD4 T cell receptors. The company has created a libr... Read More
